The Global HCC (Hepatocellular Carcinoma) Market was valued at USD 3.5 billion in 2024 and is projected to reach a market size of USD 9.85 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 22.99%.
Hepatocellular carcinoma, HCC is an oncological disease resulting from the multiplication of cancerous cells in the hepatocytes or liver cells. It is a rather dangerous illness that can destroy hepatic cells and interfere with their functions to put dangerous complications in the way of life. Depending on the HCC stage and size, the symptoms might change, and a lot of patients may have no signs. Some of the non-specific symptoms include abdominal pain, nausea, vomiting, tiredness, etc. Patients with hepatocellular carcinoma may also present with yellow skin, loss of appetite, abdominal swelling, unintentional weight loss, easy bruising, etc. The diagnosis of this disease is usually based on the patient's symptoms, blood testing, and imaging evaluation. The healthcare provider may also perform numerous diagnostic procedures, such as multi-phase computerized tomography scans and contrast-enhanced magnetic resonance imaging, to detect disease staging among patients. Additionally, a biopsy or ultrasound of the tumor is required to confirm the diagnosis of hepatocellular carcinoma. The latest research from IMARC Group offers a thorough examination of the hepatocellular carcinoma markets in the US, UK, Japan, and EU4 (Germany, Spain, Italy, and France). Treatment methods, in-market, and pipeline medications, the market share of specific therapies, the performance of the seven main markets, the performance of important firms and their medications, etc. are all included in this. The patient pool for the seven main markets, both present and future, is also included in the report. The survey claims that both the patient pool and the market for hepatocellular carcinoma treatment are the largest in the United States. The study has also included information on the existing treatment practice/algorithm, market drivers, opportunities, challenges, reimbursement scenarios, unmet medical needs, etc.
Key Market Insights:
Positive results from Geneos Therapeutics' Phase I/II GT-30 clinical study of GNOS-PV02, a customized neoantigen vaccine, in conjunction with pembrolizumab for advanced hepatocellular cancer, were reported in April 2024. Nearly one-third of patients treated with this combination therapy showed tumor shrinking, according to the findings, and three of those patients achieved a complete response, meaning that after a median follow-up of 21.5 months, no visible tumor indications remained.
At the 2023 AASLD Liver Meeting in Boston, Massachusetts, in November 2023, SCG Cell Therapy Pte Ltd (SCG) unveiled late-breaking clinical results from its first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) treatment, SCG101. SCG101 showed possible antiviral and anticancer effects in individuals with advanced HBV-related hepatocellular carcinoma in a first-in-human clinical trial.
Tvardi Therapeutics, Inc. announced in June 2023 that the first subjects in each arm of its ongoing REVERT LIVER CANCER research had received their doses. In patients with locally advanced or metastatic and incurable hepatocellular carcinoma, the trial assesses the safety and therapeutic efficacy of TTI-101 both as a monotherapy and in combination with standard-of-care treatment.
Genoscience Pharma said in February 2023 that the US FDA has granted their top candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, Orphan Drug Designation (ODD) for the treatment of hepatocellular cancer
HCC (Hepatocellular Carcinoma) Market Drivers:
The growing prevalence of lifestyle diseases is one of the major drivers of the hepatocellular carcinoma treatment market growth.
The liver is greatly impacted by lifestyle disorders like diabetes, obesity, and high blood pressure, which are also some of the main causes of hepatocellular carcinoma. The need for hepatocellular carcinoma treatment will increase due to the growing prevalence of lifestyle illnesses. One of the main forms of liver disease is non-alcoholic fatty liver disease (NAFLD). In Western nations, NAFLD affects 20% to 30% of the general population, according to the NIH. Additionally, those who have type 2 diabetes (70%) and obesity (90%) have higher prevalence rates of NAFLD. Since the prevalence of NAFLD has a significant impact on hepatocellular carcinoma, if treatment is not received, the market for hepatocellular carcinoma treatments will eventually benefit from the high prevalence of lifestyle illnesses.
The high availability of therapies and chemotherapy drugs is giving rise to market growth.
The industry is changing as a result of new technology being included in non-melanoma skin cancer treatment devices. Cutting-edge technologies like photodynamic therapy (PDT), laser therapy, and cryotherapy offer non-invasive treatment options that precisely target cancerous cells with the least amount of tissue damage possible. Robotic surgery enhances surgical precision in challenging situations, and artificial intelligence (AI) increases diagnostic accuracy by enabling early detection. Additionally, follow-up therapy and remote patient monitoring are made possible via wearable technology and telemedicine systems. The market for non-melanoma skin cancer is expanding as a result of these technological advancements, which are also boosting treatment results, reducing recovery times, and enhancing patient comfort.
HCC (Hepatocellular Carcinoma) Market Restraints and Challenges:
Aversion to Side Effects, as well as the high cost involved, will Limit Market Growth.
One of the main obstacles to the expansion of the hepatocellular carcinoma treatment market is the high side effects of the existing medicines, particularly chemotherapy medications. In addition to decreasing patient compliance, severe adverse effects of liver disease treatment medications may also lead to patient dropouts, which lowers demand for the medications and, ultimately, their sales. These medications come in a variety of combinations and dose formats. Common adverse effects include sleepiness, alopecia, urine retention, dry eyes, dry mouth, diarrhea, and visual impairment. When giving these medications to older people who have dementia or cognitive impairment, care must be exercised because the medications may exacerbate their symptoms. Even though these medications are prescribed to children, taking more of them than is allowed can have major negative effects. Urinary tract infections and headaches are the most often reported adverse effects. Constipation, diarrhea, rash, abdominal pain, and heart palpitations are a few uncommon adverse effects. Consequently, the possible adverse effects of hepatocellular carcinoma medications hinder the justification for their usage in treating the disease, which has a detrimental effect on the market's expansion.
HCC (Hepatocellular Carcinoma) Market Opportunities:
The market for hepatocellular carcinoma (HCC) offers a number of encouraging prospects for expansion and advancement. The need for HCC treatments is growing as chronic liver illnesses including hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) become more common. Patient outcomes are being improved by new treatment choices like as immunotherapy, targeted treatments, and minimally invasive procedures. Advances in AI and machine learning in particular are improving diagnostic precision and making it possible to identify HCC early. Growing awareness and advancements in healthcare infrastructure indicate substantial development potential in emerging economies in Latin America and Asia-Pacific. Patients with HCC now have new hope thanks to research and development initiatives that are producing innovative medications and therapies. Patient satisfaction and treatment effectiveness are increasing as a result of customized treatment programs made to fit each patient's unique profile. New medicines are being developed more quickly thanks to strategic alliances and collaborations between pharmaceutical corporations, academic institutions, and healthcare providers. In the upcoming years, it is anticipated that these changes will propel the expansion of the HCC market and enhance patient outcomes.
HCC MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2024 - 2030 |
|
Base Year |
2024 |
|
Forecast Period |
2025 - 2030 |
|
CAGR |
22.99% |
|
Segments Covered |
By Treatment Type, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Novartis AG, Bayer AG, Merck & Co, Celgene Corporation, Bristol- Myers Squibb, Amgen Inc., Teva Pharmaceuticals Industries , AbbVie Inc., Johnson & Johnson Services |
Interventional Radiology
Chemotherapy
Radiation Therapy
Surgery
Targeted Therapy
Immunotherapy
The market for hepatocellular carcinoma (HCC) is divided into therapeutic categories, each of which offers a unique strategy for treating the condition. Interventional radiology encompasses minimally invasive techniques that directly target cancer cells, such as radiofrequency ablation, chemoembolization, and intra-arterial chemotherapy. Interventional radiology is becoming more and more in demand because of its accuracy and effectiveness in treating localized malignancies. Chemotherapy is still an essential aspect of treating HCC, especially when the disease is advanced and surgery is not an option. It is frequently used either alone or in conjunction with other medications, despite its negative consequences. The precision and efficacy of radiation therapy, which utilizes high-energy radiation to kill cancer cells, have increased, making it a good choice for patients who are unable to have surgery. For localized HCC, surgical excision is another popular therapeutic option. Liver transplantation may also be explored in certain circumstances. Success rates have increased dramatically as a result of improvements in surgical methods and post-operative care. A significant advancement in the treatment of HCC targeted therapies targets certain chemicals implicated in the formation of cancer and offers safer and more effective alternatives to conventional chemotherapy. Immunocheckpoint inhibitors are increasingly being used in immunotherapy, which boosts the body's immune system to combat cancer cells. Immunotherapy has had encouraging outcomes, especially in advanced stages. All of these therapy options are essential to the overall management of HCC because they enable individualized strategies based on the needs of the patient and the course of the disease.
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgery Centers
End users, who are essential to patient care and treatment delivery, make up the market for hepatocellular carcinoma (HCC). Because they provide access to trained oncologists, multimodal treatment techniques, and sophisticated diagnostic technologies, hospitals serve as the main treatment facilities for HCC. They deal with a lot of situations, especially those involving radiation therapy, chemotherapy, and surgery. Clinics act as secondary care providers, emphasizing follow-up care for patients receiving long-term management, early diagnosis, and outpatient therapies. Cancer rehabilitation facilities focus on post-treatment care, enhancing patients' quality of life by providing physical therapy, dietary guidance, and psychological support.
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Due to the rising incidence of chronic liver diseases and the growing number of clinical trials for cancer treatment conducted by manufacturers to meet patients' unmet medical needs, North America is anticipated to maintain a leading position in the global market for hepatocellular carcinoma treatment during the forecast period. According to a 2017 survey by the University of California, Los Angeles' (UCLA) Health Science Department, hepatocellular carcinoma (HCC) accounts for over 70.0% of all liver cancer diagnoses in the United States. An estimated 40,000 people received a liver cancer diagnosis in 2017, and more than 28,000 deaths were attributed to HCC. Because more manufacturers in the area are conducting research and development to create efficient medicines and treatment methods for hepatocellular carcinoma, Europe and Asia Pacific are anticipated to see a notable compound annual growth rate (CAGR) over the projected period. The World Health Organization estimates that 36,000 persons in Japan and 63,000 in Europe received a liver cancer diagnosis in 2017.
COVID-19 Impact Analysis on the Global HCC (Hepatocellular Carcinoma) Market:
The global market for hepatocellular carcinoma (HCC) has been significantly impacted by the COVID-19 pandemic. At first, the pandemic caused fewer HCC cases to be diagnosed and treated because medical resources were diverted to treating COVID-19 cases. The detection and treatment of HCC were delayed as a result of the cancellation or postponement of numerous elective procedures and routine examinations. However, the need for HCC therapies increased again as healthcare systems adjusted to the new normal. The quicker uptake of telemedicine and remote monitoring, which enabled patients to continue their therapy without frequent hospital stays, has been one benefit. The epidemic also brought attention to the significance of a strong healthcare system and the demand for cutting-edge therapeutic approaches. New medications and treatments for HCC were approved as a result of pharmaceutical companies' greater emphasis on research and development. All things considered, even while the pandemic originally caused problems with HCC therapy, it also spurred improvements in healthcare delivery and available treatments, which eventually helped HCC patients.
Latest Trends/ Developments:
The market for non-melanoma skin cancer is expanding significantly in 2024 as a result of a number of developments and trends. New therapies like checkpoint inhibitors and bispecific antibodies are demonstrating encouraging outcomes for advanced cases as immunotherapy continues to advance. With up to 95% accuracy rates, AI-driven diagnostics are improving the identification of skin cancer. Because they provide accurate targeting and treatment, minimally invasive surgical procedures like image-guided superficial radiation therapy are growing in popularity. Programs for screening and greater awareness are essential for early detection, which improves patient outcomes. Because of greater knowledge and advancements in healthcare infrastructure, emerging regions in Asia-Pacific and Latin America exhibit substantial development potential. Additionally, patients who might not be good candidates for surgery now have additional therapeutic alternatives thanks to the development of innovative topical medicines and photodynamic therapies. New medicines are being developed more quickly thanks to strategic alliances and collaborations between pharmaceutical corporations, academic institutions, and healthcare providers. Personalized treatment regimens that cater to each patient's specific needs are becoming increasingly prevalent as patient-centric care gains more attention. Additionally, the market is witnessing a surge in financing and expenditure for research and development, which is anticipated to propel additional improvements in the years to come.
Key Players:
Novartis AG
Bayer AG
Merck & Co
Celgene Corporation
Bristol- Myers Squibb
Amgen Inc.
Teva Pharmaceuticals Industries
AbbVie Inc.
Johnson & Johnson Services
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Global HCC (Hepatocellular Carcinoma) Market was valued at USD 3.5 billion in 2024 and is projected to reach a market size of USD 9.85 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 22.99 %.
Non-melanoma Skin Cancer Cases Are Growing Globally to Boost Market Growth.
Based on Service Provider, the Global HCC (Hepatocellular Carcinoma) Market is segmented into Hospitals, Ambulatory Surgical Centers, Clinics, and Cancer Rehabilitation Centers.
North America is the most dominant region for the Global HCC (Hepatocellular Carcinoma) Market.
Novartis AG, Merck & Co., Celgene Corporation, Amgen Inc., Bristol-Myers Squibb, Teva Pharmaceutical, and Bayer, are the key players operating in the Global HCC (Hepatocellular Carcinoma) Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
